A Case of Autoimmune Hypophysitis Associated with Asymptomatic Primary Biliary Cirrhosis

MASATERU NISHIKI, YOSHIO MURAKAMI, KUNIO KOSHIMURA, MOTOI SOHMIYA, JUNKO TANAKA, SHIGEKI YABE*, ISAO KOBAYASHI* AND YUZURU KATO

First Division, Department of Medicine, Shimane Medical University, Shimane 693-8501, and *Department of Laboratory Medicine and Clinical Laboratory Center, Gunma University School of Medicine, Gunma 371-8511, Japan

Abstract. We report a 61-year old male patient with panhypopituitarism complicated with asymptomatic primary biliary cirrhosis (PBC). T1-weighted magnetic resonance imaging demonstrated high intensity of the anterior pituitary gland. There was no mass lesion or enlargement of the pituitary gland or the stalk. Immunoblot analysis of the patient's sera with rat pituitary antigens revealed a band with a molecular size of 22 kD. Anti-M2 mitochondrial antibody has been consistently positive for five years. Liver biopsy revealed portal hepatitis with perportal infiltration of the inflammatory cells. This is the first case report of autoimmune hypophysitis complicated with asymptomatic PBC.

Key words: Anti-pituitary antibody, Anti-mitochondrial antibody, Asymptomatic primary biliary cirrhosis, Hypopituitarism

Case Report

A 56-year old man was admitted to a hospital after an episode of palpitation, cold sweating and weakness five years earlier. Hypotension and hypoglycemia were relieved by treatment with hydrocortisone, and the patient was transferred to our hospital for further examination.

On physical examination, his blood pressure was 90/68 mmHg, and pulse rate was 64/min, regular. The visual field and the acuity were normal. Goiter was not palpable. Axillary and pubic hair distributions were normal.

Hematological and biochemical laboratory data showed no remarkable abnormalities except mild anemia (Hb: 11.8 g/dl). Serum electrolyte and transaminferase levels were within normal limits. Endocrinological tests revealed impaired secretion of ACTH, GH, PRL and gonadotropins (Table 1, Fig. 1). Diabetes insipidus was not present. Serum anti-mitochondrial antibody was positive at a
dilution of 1:160 by immunofluorescence. Serum IgM and IgG anti-M₂ mitochondrial antibodies were 700 U/ml and 368 U/ml, respectively as determined by enzyme immunoassay [6]. Anti-pituitary antibody was examined by immunoblot analysis as previously described by Yabe et al. [7]. As shown in Fig. 2, a major band was identified at 22 kD. A minor band also was seen at 49 kD, presumably due to anti-M₂ mitochondrial antibody.

T1-weighted image of magnetic resonance imaging (MRI) demonstrated a heterogenous high intensity in the anterior lobe of the pituitary gland. The posterior lobe and the stalk were normal (Fig. 3).

This patient has been treated with hydrocortisone for five years. During the treatment, daily excretion of urinary 17-OHCS remained within the normal range, and neither clinical signs nor laboratory findings indicated adrenal insufficiency. Serum transaminose levels remained within normal limits. Serum IgM (1256 U/ml) and IgG (605 U/ml) anti-M₂ mitochondrial antibodies were consistently high.

Liver biopsy was performed to evaluate the liver histology and revealed portal hepatitis with periportal infiltration of inflammatory cells (Fig.

Table 1. Laboratory findings on admission

<table>
<thead>
<tr>
<th>Endocrine</th>
<th>Aldosterone</th>
<th>17OHCs</th>
<th>17KS</th>
<th>AMA</th>
<th>Anti-M₂, M₂ type of AMA</th>
<th>Anti-M₂, M₂ type of AMA</th>
<th>TGHA</th>
<th>Anti-M₂, M₂ type of AMA</th>
<th>MCHA</th>
<th>Anti-M₂, M₂ type of AMA</th>
</tr>
</thead>
<tbody>
<tr>
<td>GH &lt;0.3 ng/ml</td>
<td>3.8 ng/dl</td>
<td>0.6 mg/day</td>
<td>1.8 mg/day</td>
<td>17OHCs</td>
<td>17KS</td>
<td>AMA</td>
<td>Anti-M₂, M₂ type of AMA</td>
<td>TGHA</td>
<td>Anti-M₂, M₂ type of AMA</td>
<td>MCHA</td>
</tr>
<tr>
<td>PRL 2.4 ng/ml</td>
<td>C3</td>
<td>51 mg/dl</td>
<td>41.9 mg/dl</td>
<td>17OHCs</td>
<td>17KS</td>
<td>AMA</td>
<td>Anti-M₂, M₂ type of AMA</td>
<td>TGHA</td>
<td>Anti-M₂, M₂ type of AMA</td>
<td>MCHA</td>
</tr>
<tr>
<td>ADH 1.1 pg/ml</td>
<td>6.6 µg/dl</td>
<td>1149 mg/dl</td>
<td>166 mg/dl</td>
<td>17OHCs</td>
<td>17KS</td>
<td>AMA</td>
<td>Anti-M₂, M₂ type of AMA</td>
<td>TGHA</td>
<td>Anti-M₂, M₂ type of AMA</td>
<td>MCHA</td>
</tr>
<tr>
<td>TSH 6.5 µ/U/ml</td>
<td>C4</td>
<td>34.5 U/ml</td>
<td>17OHCs</td>
<td>17KS</td>
<td>AMA</td>
<td>Anti-M₂, M₂ type of AMA</td>
<td>TGHA</td>
<td>Anti-M₂, M₂ type of AMA</td>
<td>MCHA</td>
<td>Anti-M₂, M₂ type of AMA</td>
</tr>
<tr>
<td>T3 120 ng/dl</td>
<td>lgG</td>
<td>368 U/ml</td>
<td>17OHCs</td>
<td>17KS</td>
<td>AMA</td>
<td>Anti-M₂, M₂ type of AMA</td>
<td>TGHA</td>
<td>Anti-M₂, M₂ type of AMA</td>
<td>MCHA</td>
<td>Anti-M₂, M₂ type of AMA</td>
</tr>
<tr>
<td>T4 6.6 µg/dl</td>
<td>IgM</td>
<td>166 mg/dl</td>
<td>17OHCs</td>
<td>17KS</td>
<td>AMA</td>
<td>Anti-M₂, M₂ type of AMA</td>
<td>TGHA</td>
<td>Anti-M₂, M₂ type of AMA</td>
<td>MCHA</td>
<td>Anti-M₂, M₂ type of AMA</td>
</tr>
<tr>
<td>Free T4 0.8 ng/dl</td>
<td>lgA</td>
<td>277 mg/dl</td>
<td>17OHCs</td>
<td>17KS</td>
<td>AMA</td>
<td>Anti-M₂, M₂ type of AMA</td>
<td>TGHA</td>
<td>Anti-M₂, M₂ type of AMA</td>
<td>MCHA</td>
<td>Anti-M₂, M₂ type of AMA</td>
</tr>
<tr>
<td>LH 3.2 mlU/ml</td>
<td>1 x 160</td>
<td>17OHCs</td>
<td>17KS</td>
<td>AMA</td>
<td>Anti-M₂, M₂ type of AMA</td>
<td>TGHA</td>
<td>Anti-M₂, M₂ type of AMA</td>
<td>MCHA</td>
<td>Anti-M₂, M₂ type of AMA</td>
<td></td>
</tr>
<tr>
<td>FSH 3.1 mlU/ml</td>
<td>Anti-M₂lgM</td>
<td>700 U/ml</td>
<td>17OHCs</td>
<td>17KS</td>
<td>AMA</td>
<td>Anti-M₂, M₂ type of AMA</td>
<td>TGHA</td>
<td>Anti-M₂, M₂ type of AMA</td>
<td>MCHA</td>
<td>Anti-M₂, M₂ type of AMA</td>
</tr>
<tr>
<td>Testosterone 328 ng/dl</td>
<td>Anti-M₂lgG</td>
<td>368 U/ml</td>
<td>17OHCs</td>
<td>17KS</td>
<td>AMA</td>
<td>Anti-M₂, M₂ type of AMA</td>
<td>TGHA</td>
<td>Anti-M₂, M₂ type of AMA</td>
<td>MCHA</td>
<td>Anti-M₂, M₂ type of AMA</td>
</tr>
<tr>
<td>ACTH 11 pg/ml</td>
<td>TGHA</td>
<td>&lt;×100</td>
<td>17OHCs</td>
<td>17KS</td>
<td>AMA</td>
<td>Anti-M₂, M₂ type of AMA</td>
<td>TGHA</td>
<td>Anti-M₂, M₂ type of AMA</td>
<td>MCHA</td>
<td>Anti-M₂, M₂ type of AMA</td>
</tr>
<tr>
<td>Cortisol 0.37 µg/dl</td>
<td>MCHA</td>
<td>&lt;×100</td>
<td>17OHCs</td>
<td>17KS</td>
<td>AMA</td>
<td>Anti-M₂, M₂ type of AMA</td>
<td>TGHA</td>
<td>Anti-M₂, M₂ type of AMA</td>
<td>MCHA</td>
<td>Anti-M₂, M₂ type of AMA</td>
</tr>
</tbody>
</table>

17OHCs, 17-hydroxycorticosteroids; 17KS, 17-ketosteroids; AMA, anti-mitochondrial antibody; anti-M₂, M₂ type of AMA; TGHA, anti-thyroglobulin antibody; MCHA, anti-microsomal antibody.

Fig. 1. Endocrinological provocative tests. Upper panels; plasma GH responses to GHRH, insulin-induced hypoglycemia and arginine. Lower panels; plasma ACTH, TSH and prolactin, and gonadotropin response to CRH, TRH and LHRH, respectively.
FIG. 2. Immunoblot analysis of the patient's sera with rat pituitary antigens. Rat pituitary antigens were electrophoresed in polyacrylamide gel, transferred to a PVDF membrane, and were reacted with the patient's serum (dilution: 1: 101), followed by the avidin biotin peroxidase complex method. Lane 1: positive control serum, Lane 2: patient's serum (February 1992), Lane 3: patient's serum (January 1996).

FIG. 3. T1-weighted MRI images. Left: coronal, plain. Middle: coronal, gadolinium (Gd) enhancement. Right: sagittal, Gd enhancement. Note the high intensity in the anterior pituitary gland. No enlargement of the pituitary gland or the stalk was found.

FIG. 4. Histology of the liver (x 400) shows periportal infiltration of inflammatory cells. No granuloma or destruction of bile ducts was found.

Discussion

Autoimmune hypophysitis is characterized by lymphocytic infiltration into the pituitary gland [2, 3] and by the presence of anti-pituitary antibody in the serum [7, 9, 10]. In the present case, the detection of anti-pituitary antibody by a conventional immunofluorescence method was interfered by an anti-mitochondrial antibody, but immunoblotting with antigens of rat pituitary gland revealed an antibody to the antigen with a molecular size of 22 kDa.

Anti-M2 mitochondrial antibody was consistently positive in the present case. Nine types of anti-mitochondrial antibody (M1–M9) have been described. Among them, anti-M2 mitochondrial antibody is the most specific for PBC [4, 5]. There have been several case reports of autoimmune endocrine diseases associated with positive anti-mitochondrial antibodies. Perros et al. [11] reported two patients with Graves' disease in whom
anti-mitochondrial antibody was detected. In these patients, anti-M2 mitochondrial antibody was negative and there was no liver dysfunction. A few autoimmune hypophysitis patients with positive anti-mitochondrial antibody have been described [2, 3], but no detailed information on antibody subtypes, liver function or histology is available.

Portal hepatitis with periporal inflammation was demonstrated in the liver biopsy in the present case. Neither granuloma nor nonsuppurative destructive cholangitis was noted. According to the morphological staging by Ludwig et al. [8], these findings correspond to portal stage of PBC. Anti-M2 mitochondrial antibody of the IgM type is generally found in patients with asymptomatic PBC, and seroconversion from IgM to IgG antibody often indicates progression of the disease [5, 6]. In our patient, no clinical liver dysfunction has been found during the clinical course for five years. This might be related to the fact that IgM anti-M2 mitochondrial antibody has been positive without seroconversion to IgG type. Although asymptomatic PBC patients usually have a favorable prognosis, it sometimes takes more than ten years for the asymptomatic PBC to develop into the stages of advanced histologic lesions and clinical liver dysfunctions [12].

In summary, we report an old male case of lymphocytic hypophysitis complicated with asymptomatic PBC. Anti-pituitary antibody and anti-mitochondrial antibody were demonstrated in the serum. Histopathological examination of the liver demonstrated portal hepatitis with periportal inflammation. These findings suggest that anti-M2 mitochondrial antibody might have pathophysiological significance in this patient with autoimmune hypophysitis in the development of PBC.

Acknowledgments

This work was supported in part by grants from the Ministry of Health and Welfare, Japan.

References